Colitis induced by immune checkpoint inhibitors: Anti-CTLA-4 antibodies and anti-PD-1/PDL-1 antibodies

被引：1
|
作者：
Vozy, A. [1 ]
Coutzac, C. [1 ]
机构：
[1] Gustave Roussy Canc Campus, Lab Immunomonitoring Oncol, 39 Rue Camille Desmoulins, F-94805 Villejuif, France
来源：
ONCOLOGIE | 2016年 / 18卷 / 9-10期
关键词：
Colitis; CTLA-4; PD-1/PDL-1; Biomarkers; Guidelines; RESISTANT PROSTATE-CANCER; T-LYMPHOCYTE ANTIGEN-4; PHASE-II TRIAL; OPEN-LABEL; MONOCLONAL-ANTIBODY; ADVERSE EVENTS; DOUBLE-BLIND; STAGE-III; IPILIMUMAB; NIVOLUMAB;
D O I：
10.1007/s10269-016-2658-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The immune check point inhibitors, anti-CTLA-4 and anti-PD-1/PDL-1 antibodies are promising and involved in overall survival improvement. Inflammatory colitis is one of the most frequent toxicity induced by this treatment. Colitis could be severe and this could lead to discontinuation of the therapy. Currently, many studies are conducted to understand pathophysiology and to find predictive biomarkers of colitis. The goal is to improve patients selection. The aim of this review is to help practician to recognize and treat colitis early and also have an approach to meet new research challenges.
引用
收藏
页码：501 / 508
页数：8
相关论文
共 50 条
  • [1] Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
    Kaehler, Katharina C.
    Hassel, Jessica C.
    Heinzerling, Lucie
    Loquai, Carmen
    Moessner, Rotraut
    Ugurel, Selma
    Zimmer, Lisa
    Gutzmer, Ralf
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 (07): : 662 - 681
  • [2] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
    Robert, Caroline
    Mateus, Christina
    [J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
  • [3] Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis
    Huang, Yi
    Chen, Zhijian
    Shen, Gang
    Fang, Shuogui
    Zheng, Junjiong
    Chi, Zepai
    Zhang, Yuanfeng
    Zou, Yitong
    Gan, Qinghua
    Liao, Chengxiao
    Yao, Yuhui
    Kong, Jianqiu
    Fan, Xinxiang
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [4] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
    Boutros, Celine
    Tarhini, Ahmad
    Routier, Emilie
    Lambotte, Olivier
    Ladurie, Francois Leroy
    Carbonnel, Franck
    Izzeddine, Hassane
    Marabelle, Aurelien
    Champiat, Stephane
    Berdelou, Armandine
    Lanoy, Emilie
    Texier, Matthieu
    Libenciuc, Cristina
    Eggermont, Alexander M. M.
    Soria, Jean-Charles
    Mateus, Christine
    Robert, Caroline
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) : 473 - 486
  • [5] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
    Celine Boutros
    Ahmad Tarhini
    Emilie Routier
    Olivier Lambotte
    Francois Leroy Ladurie
    Franck Carbonnel
    Hassane Izzeddine
    Aurelien Marabelle
    Stephane Champiat
    Armandine Berdelou
    Emilie Lanoy
    Matthieu Texier
    Cristina Libenciuc
    Alexander M. M. Eggermont
    Jean-Charles Soria
    Christine Mateus
    Caroline Robert
    [J]. Nature Reviews Clinical Oncology, 2016, 13 : 473 - 486
  • [6] Opportunistic autoimmune disorcers potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
    Kong, Yi-chi M.
    Flynn, Jeffrey C.
    [J]. FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [7] Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
    Afzal, Muhammad Zubair
    Mercado, Rima R.
    Shirai, Keisuke
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [8] Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies
    Reck, Martin
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
  • [9] Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment
    Passat, Tilda
    Touchefeu, Yann
    Gervois, Nadine
    Jarry, Anne
    Bossard, Celine
    Bennouna, Jaafar
    [J]. BULLETIN DU CANCER, 2018, 105 (11) : 1033 - 1041
  • [10] Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: A case report
    Sone, Kenbun
    Kukita, Asako
    Masui, Yuri
    Yamada, Daisuke
    Shinozaki-Ushiku, Aya
    Kawata, Akira
    Taguchi, Ayumi
    Miyamoto, Yuichiro
    Tanikawa, Michihiro
    Iriyama, Takayuki
    Tsuruga, Tetsushi
    Osuga, Yutaka
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (03)
12345